Medical device NPI sits at the intersection of two forces that don't naturally cooperate: the pressure to move fast, and the regulatory imperative to document everything.
Teams are managing design controls, requirements, end-to-end traceability, including V&V, DHF, design transfer handoffs to contract manufacturers, and supplier onboarding—often across siloed systems that weren't built to share data with each other.
The result is predictable. CMs build to the wrong superseded revisions. V&V cycles get repeated because requirements weren't properly traced to outputs. The DHF is assembled in a sprint before the FDA inspection rather than maintained as a living record. And IP travels over email to suppliers who shouldn't have access to anything beyond their specific scope.
For Oracle Agile PLM users in MedTech, these aren't just edge cases. They're compounding structural costs of an architecture that silos product, quality, and supplier data instead of unifying them. Propel was built to close those gaps, natively, on a single platform.
Here are five ways that changes NPI execution for MedTech teams:
1. Cross-Functional Launch Execution That Doesn't Collapse Under Compliance Weight
Who it helps: Product and Program Leaders
MedTech NPI fails most often not in the lab but in the handoffs: when design assumptions don't reach manufacturing, when quality events from prior programs don't inform the next design, when phase-gate decisions are made without current data because the right people weren't looking at the same record. Sequential, siloed execution is the norm, and it's the primary driver of redesign cycles, repeat testing, and launch delays.
Propel connects every NPI stakeholder to the same live product thread:
- Parallel workflows replace sequential hand-offs, so quality, engineering, regulatory, and procurement teams work simultaneously against the same product record—not against their own copies of it
- Design controls natively integrated with PLM—user needs, design inputs, design outputs, verification and validation—so traceability builds continuously through development, not assembled retroactively before a submission
- Phase-gate and project management built into the platform gives program leaders visibility into milestone status, open tasks, and at-risk items without requiring a separate project management tool
- Closed-loop quality from the start—quality events and CAPA from prior programs are visible during NPD, so known failure modes don't get designed into the next device
When the product record, design controls, and quality history are unified, the information a team needs to make a gate decision is already there.
2. Design Transfer That Reaches the Right Revision Every Time
Who it helps: Engineering Leaders and Supplier Quality Engineers
Design transfer is a point of highest risk in the MedTech NPI lifecycle. A contract manufacturer building to the wrong revision—because the approved drawing was sent by email three change orders ago—inevitably results in a quality event. In a worst case, it triggers a recall. The manual handoff model that most teams rely on isn't just inefficient; it's a regulatory risk with a paper trail that often fails under audit.
Propel seamlessly governs the design transfer process end-to-end:
- Secure supplier portal provides contract manufacturers with authenticated, role-based access to strictly the BOM, drawings, and specifications they're authorized to see—always at the current approved revision, never a moment behind
- Device Master Record (DMR) maintained natively within the product record, so the document package that defines the device is always current, always traceable, and always tied to the change history that produced it
- Engineering change orders can automatically trigger supplier notifications, so CMs are never operating on stale data because nobody remembered to send an email
- Full audit trail from design session to approved revision to supplier access—the kind of traceability that turns an FDA inspection on design controls from a scramble into an audit-ready walkthrough
When design transfer handoff is governed rather than informal, the CM always builds to the right revision. That's not just an efficiency gain—it's a compliance posture.
MORE: Curious what design transfer looks like on a platform built for MedTech compliance? Read our Life After Agile ebook.
3. A Platform That IT Can Govern and Engineers Will Actually Use
Who it helps: IT and Technical Decision-Makers
MedTech companies face systemic IT problems when using Oracle Agile PLM’s disconnected system layers. The Java-based client architecture introduces known security vulnerabilities that are huge risks when sharing design data with external partners. Role-based access controls are coarse and difficult to configure precisely. And every new business requirement—a new workflow, a new document type, a new supplier access level—requires custom development against an architecture that was never designed to be extensible.
Propel replaces that antiquated architecture with a modern platform purpose-built for MedTech requirements:
- Fine-grained, role-based access controls govern exactly what each internal user and external supplier can see at the product, BOM, component, and document level
- Salesforce-native world-class security provides the multi-layered data protection and audit infrastructure that MedTech companies need—without requiring custom hardening
- Low/no-code configuration means workflow changes, new object types, and process adjustments are made without Java development and PXs, keeping the business moving at business speed rather than IT speed
- Validation-ready IQ/OQ/PQ documentation reduces the validation burden of system changes, a significant cost driver in regulated environments
Modern architecture isn't a nice-to-have in MedTech. It's what allows the platform to keep pace with both the product and the regulatory environment it operates in.
4. NPI Timelines and Margins That Leadership Can Actually Realize
Who it helps: Executive and Finance Leaders
MedTech product launches are expensive to plan and catastrophic to delay. The revenue window for a first-mover device is a real advantage; the premium pricing that early market entry captures doesn't wait. And yet most executive teams have limited visibility into NPI pipeline health—phase-gate status, open quality issues, component risk, and BOM cost—because that information lives across siloed systems nobody has aggregated.
Propel makes the financial and operational levers of NPI visible in real time:
- NPI pipeline dashboards surface phase-gate status, open tasks, and at-risk milestones before they become schedule slips
- Costed BOM rollup with real-time component pricing means product cost is known during design, not discovered at manufacturing ramp
- Component risk and availability data integrated into the BOM flags high-risk or sole-sourced parts early enough to qualify alternates before they stall production
- Cost of poor quality reduced structurally, when design quality is enforced from the start with proper traceability, the rework cycles and repeat V&V runs that consume NPI budgets occur less, and are better-documented when they do
First to market at the right cost is a leadership outcome. Propel gives leadership the data to steer toward it.
5. Supplier Readiness as Part of the NPI Process, Not an Afterthought
Who it helps: Procurement and Legal Teams
In MedTech NPI, supplier onboarding is a compliance activity, not just a commercial one. Suppliers need to be qualified, audited, and trained on current device specifications before they can manufacture to design. When that process runs in a separate system—or worse, over email—it creates gaps in the documentation chain that surface during FDA inspections or, more expensively, during production.
Propel embeds procurement and supplier readiness into the NPI thread:
1. Earlier involvement. AML/AVL data integrated into BOM development means procurement sees component decisions as engineering makes them—enabling real-time input on cost, availability, and compliance before parts are locked.
2. Qualification built into the workflow. Supplier evaluation, onboarding, and audit processes run within the same platform as the product record—creating a connected, traceable supplier qualification history that holds up under regulatory scrutiny.
3. Production ramp without IP leakage. Secure, role-based supplier access means CMs and strategic suppliers are brought into the product thread in a governed, auditable way—with access limited to what each relationship specifically requires, and nothing beyond it.
When supplier readiness is part of the NPI process rather than a parallel track that has to be reconciled, launch readiness and regulatory readiness arrive at the same time.
MORE: How exposed is your NPD process if you stay on Agile? Take the quiz to find out.
What It Looks Like in Practice
Modernizing NPD processes leads to proven business outcomes.
Accelerated change impact assessments by 73%.
Surmodics, a leader in medical device and in vitro diagnostic technologies, was missing core capabilities like change impact assessment and integrated BOM management. With Propel's unified PLM/QMS, change impact assessments accelerated by 73%, CAPA cycle time dropped from 278 days to 73, and five paper forms collapsed into a single digital workflow. Read case study.
77% faster product development. 186% ROI.
Breg, a medical device company specializing in orthopedic bracing and cold therapy, had product and supplier data scattered across 20 disconnected systems. After consolidating onto Propel's unified PLM and QMS, product development time fell by 77%, time spent on quality document control dropped 50%, and user satisfaction reached 91%. Nucleus Research independently verified a 186% ROI within 13 months. Read case study.
NPI That Arrives on Time, on Budget, and Audit-Ready
MedTech NPI doesn't have margin for the failures that fragmented systems produce. A CM building to the wrong revision, a V&V cycle repeated because requirements traceability broke down, a DHF assembled the week before inspection—these aren't operational inconveniences. They're compounding costs that erode the margin and timeline advantage that first-mover launches are supposed to deliver.
For Oracle Agile PLM users, these are structural liabilities of an architecture that was never designed to unify design, quality, and supplier data in a single governed thread.
Propel was built to make unification the default, not the destination.
See what compliant, connected MedTech NPI looks like on a modern platform. Get a demo of Propel Software today.
FAQ
Q: What makes MedTech NPI different from standard product development?
A: MedTech NPI operates under strict regulatory requirements—FDA 21 CFR Part 820, ISO 13485, EU MDR—that mandate design controls, traceability from user needs through verification and validation, Design History File maintenance, design transfer documentation, and supplier qualification. Every stage of development must be documented with enough rigor to withstand regulatory inspection, which makes disconnected systems a compliance liability, not just an efficiency problem.
Q: What challenges do MedTech teams face when managing NPI on Oracle Agile PLM?
A: Oracle Agile PLM separates product, quality, and supplier data into disconnected modules and systems, making it difficult to maintain continuous traceability through design controls, manage design transfer to CMs securely, or surface quality history during NPD. Known Java client security vulnerabilities create IP exposure risk in supplier collaboration, and the lack of low/no-code extensibility means every process change requires custom development.
Q: How does Propel support FDA design controls requirements?
A: Propel natively integrates design controls—user needs, design inputs, design outputs, V&V traceability—with the PLM product record, so traceability builds continuously throughout NPI rather than being assembled retroactively. DHF and DMR records are maintained natively, accessible on demand, and tied to the change history that produced them. Learn more.
Q: How does Propel govern design transfer to contract manufacturers?
A: Propel's Supplier Community provides CMs with authenticated, role-based access to the current approved BOM, drawings, and specifications—updated automatically when engineering changes are released. Engineering change orders trigger supplier notifications, eliminating the manual email-based handoff where revision mismatches originate. Every supplier interaction is logged with a full audit trail.
Q: How does Propel reduce NPI cycle times in MedTech?
A: Propel replaces sequential, siloed NPI execution with parallel cross-functional workflows on a unified product thread. Design controls, quality history, change management, and supplier data all connect to the same record—reducing redesign cycles driven by missed requirements, repeat V&V caused by traceability gaps, and production delays from supplier handoff failures.
